TOKYO, Oct 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.
Under the terms of the agreement, Eisai Inc. grants Biotoscana an exclusive license to seek regulatory approvals and commercialize the anticancer agents Halaven and Lenvima, as well as antiepileptic agents Fycompa and Inovelon in Latin America. In Mexico, however, Eisai will retain the rights to, and conduct all activities for, Halaven and Lenvima. Eisai Inc. will supply Biotoscana with the products, for which it will receive compensation, and is also entitled to a one-time payment as well as milestone payments.
Biotoscana is a pharmaceutical company operating out of 10 countries in Latin America, where it is developing a strong portfolio that includes oncology products. As a result of granting Biotoscana these licenses, Eisai can swiftly expand access in Latin American markets for its innovative new drugs, and further contribute to patients in Latin America.
Eisai positions oncology and neurology as key therapeutic areas. By accelerating the development of its innovative new drugs in these areas and pursuing optimal business models to match regional characteristics, Eisai seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients and their families all over the world.
About Grupo Biotoscana Grupo
Biotoscana is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. Grupo Biotoscana is currently present throughout 10 Latin American countries (Argentina, Uruguay, Ecuador, Colombia, Chile, Paraguay, Brazil, Peru, Bolivia, and Mexico) where it operates under its companies Biotoscana, United Medical and LKM. Grupo Biotoscana's strong portfolio combines world-class licenses and proprietary products.
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Oct 4, 2017 09:49 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.